GIURISATO EMANUELE

Emanuele
Giurisato
Dipartimento di Biotecnologie, Chimica e Farmacia
Professore Associato

Presentation

Professor Associate

Contacts

giurisato2@unisi.it
0577232125 [int.2125]

Curriculum Vitae

cv

Teaching activities

Completion accademic year: 2024/2025

GENERAL PATHOLOGY
Course year: 1 First cycle degree (DM 270) PHYSIOTHERAPY A.Y. 2024/2025
GENERAL PATHOLOGY
Course year: 1 First cycle degree (DM 270) CARDIOCIRCULATORY AND CARDIOVASCULAR PERFUSION TECHNIQUES A.Y. 2024/2025
GENERAL PATHOLOGY AND MEDICAL TERMINOLOGY
Course year: 2 Full cicle (5 years) CHIMICA E TECNOLOGIA FARMACEUTICHE A.Y. 2023/2024
GENERAL PATHOLOGY AND PATHOPHYSIOLOGY
Course year: 1 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2024/2025

Completion accademic year: 2023/2024

GENERAL PATHOLOGY AND MEDICAL TERMINOLOGY
Course year: 2 Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2022/2023

Completion accademic year: 2022/2023

Completion accademic year: 2021/2022

GENERAL PATHOLOGY AND MEDICAL TERMINOLOGY
Course year: 2 Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2020/2021

Completion accademic year: 2020/2021

Completion accademic year: 2019/2020

EXPERIMENTAL PATHOLOGY
Course year: 2 Second cycle degree (Laurea Magistrale) MEDICAL BIOTECHNOLOGIES A.Y. 2018/2019

Registration for exams

Research

 

  1. Filiberti S, Russo M, Lonardi S, Bugatti M, Vermi W, Tournier C, and Giurisato E . (2022) Self-Renewal of Macrophages: Tumor-Released Factors and Signaling Pathways. Biomedicines. Oct 26;10(11):2709. doi: 10.3390/biomedicines10112709.PMID:36359228
  2. Zhang J, Pearson A, Sabherwal N, Telfer B, Ali N, Kan K, Xu Q, Zhang W, Chen F, Li S, Wang J, Gray N, Risa-Ebrí B, Finegan KG, Cross M, Giurisato E, Whitmarsh A, and Tournier C. (2022). Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition. Cancer Research Communications 2(3): 131-145; doi.org/10.1158/2767-9764.CRC-21-0089.
  3. Monti M, Celli J, Missale F, Cersosimo F, Russo M, Belloni E, Di Matteo A, Lonardi S, Vermi W, Ghigna C, and Giurisato E. (2022). Clinical Significance and regulation of ERK5 expression and function in Cancer. Cancers,14(2), 348; https://doi.org/10.3390/cancers14020348. IF: 6.639
  4. Cersosimo F, Barbarino M, Lonardi S, Vermi W, Giordano A, Bellan C and Giurisato E (2021).Mesothelioma malignancy and the microenvironment: molecular mechanisms. Cancers Nov 12;13(22):5664. doi: 10.3390/cancers13225664.
  5. Xu Q, Zhang J, Telfer B, Zhang H, Ali N, Chen F, Risa B, Pearson AJ, Zhang W, Finegan KG, Ucar A, Giurisato E, and Tournier C (2021). The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion. Oncogene, 40(23):3929-3941. doi: 10.1038/s41388-021-01798-2.
  6. Cersosimo F, Lonardi S, Bernardini G, Telfer B, Mandelli GE, Santucci A, Vermi W, and Giurisato E (2020). Tumor-Associated Macrophages in Osteosarcoma: from mechanisms to therapy. Int. J. Mol. Sci. 21(15), 5207; doi.org/10.3390/ijms21155207.
  7. Giurisato E, Lonardi S, Telfer B, Lussoso S, Risa-Ebrí B, Zhang J, Russo I, Wang J, Santucci A, Finegan KG, Gray NS, Vermi W, and Tournier C. (2020). Extracellular-regulated protein kinase 5-mediated control of p21 expression promotes macrophage proliferation associated with tumor growth and metastasis. Can Research Jun 19:canres.2416.2019. doi: 10.1158/0008-5472.CAN-19-2416.
  8. Luiz JP, Toller-Kawahisa J, Viacava P, Nascimento D, Pereira P, Saraiva AL, Prado D, Le Bert M, Giurisato E, Tournier C, Cunha TM, Cunha FQ, Quesniaux V, Ryffel B, Alves-Filho JC. (2020). MEK5/ERK5 signaling mediates IL-4-induced M2 macrophage differentiation through regulation of c-Myc expression. J Leukoc Biol July 22. doi:10.1002/JLB.1MA0520-016R
  1. Consoli F, Barbieri G, Picciolini M, Medicina D, Bugatti M, Tovazzi V, Liserre B, Zambelli C, Zorzi F, Berruti A, Giurisato E and Vermi W (2020). Clinical and molecular characterization of a rare complex BRAF mutation involving codon V600 and K601 in primary cutaneous melanoma. Frontiers of Oncology, doi.org/10.3389/fonc.2020.01056.
  2. Pearson AJ, Fullwood P, Tapia GT, Prise I, Smith M, Xu Q, Jordan A, Giurisato E, Whitmarsh AJ, Francavilla C and Tournier C (2020). Discovery of a gatekeeper residue in the C terminal tail of the extracellular signal-regulated protein kinase 5 (ERK5). Int. J. Mol. Sci. 21(3), 929. doi.org/10.3390/ijms21030929.
  3. Benerini Gatta L, Melocchi L, Bugatti M, Missale F, Lonardi S, Cristinelli L, Belotti S, Simeone C, Ronca R, Licini S, Tardanico R, Zanetti B, Chan SR, Giurisato E, Calza S, and Vermi W. (2019) Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. Cancers (Basel). 2019 Aug 21;11(9):1219. doi: 10.3390/cancers11091219
  4. Moretti E, Collodel G, Giuseppe Belmonte, Daria Noto, Giurisato E. (2019) Defective spermatogenesis and testosterone levels in KSR1 deficient mice.  Reproduction, Fertility and Development. 2019 Apr 15. doi: 10.1071/RD18386.
  5. Giurisato E, Xu Q, Lonardi S, Telfer B, Russo I, Pearson A, Finegan KG, Wang W, Wang J, Gray NS, Vermi W, Xia Z and Tournier C. (2018). Myeloid ERK5 deficiency suppresses tumor growth by blocking pro-tumor macrophage polarization via STAT3 inhibition. Proc Natl Acad Sci U S A. Mar 20;115(12):E2801-E2810. doi: 10.1073/pnas.1707929115. PMID:29507229.
  6. Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, Sarhan AR, Hillen A, Velde GV, Gray NS, Alessi DR, Cunningham DL, Tournier C, Johnston SA, May RC (2017). Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. Science Advances 3(8): e1700898.doi:10.1126/sciadv.1700898. PMID: 28835924.
  7. Young H, Rowling E, Bugatti M, Giurisato E, Luheshi H, Arozarena I, Acosta JC, Kamarashev J, Frederick D, Cooper Z, Reuben A, Gil J, Flaherty K, Wargo J, Vermi W, Smith M, Wellbrock C, and Hurlstone A. (2017). An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Medicine 214(6):1691-1710. doi: 10.1084/jem.20160855. PMID: 28450382
  8. Giurisato E, Tournier C. (2016). Can tumour cells proliferate without ERK5? Cell Cycle. Mar 3;15(5):619-20. doi: 10.1080/15384101.2016.1143272. PMID: 26822978-

Selected publications:

  • J Pearson, A., Fullwood, P., Toro Tapia, G., Prise, I., Smith, M., Xu, Q., et al. (2020). Discovery of a gatekeeper residue in the C terminal tail of the extracellular signal-regulated protein kinase 5 (ERK5). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(3) [10.3390/ijms21030929]. - view more
  • Moretti, E., Collodel, G., Belmonte, G., Noto, D., Giurisato, E. (2019). Defective spermatogenesis and testosterone levels in kinase suppressor of Ras1 (KSR1)-deficient mice. REPRODUCTION FERTILITY AND DEVELOPMENT, 31(8), 1369-1377 [10.1071/RD18386]. - view more
  • Benerini Gatta, L., Melocchi, L., Bugatti, M., Missale, F., Lonardi, S., Zanetti, B., et al. (2019). Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. CANCERS, 11(9) [10.3390/cancers11091219]. - view more
  • Giurisato, E., Xu, Q., Lonardi, S., Telfer, B., Russo, I., Pearson, A., et al. (2018). Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 115(12), E2801-E2810 [10.1073/pnas.1707929115]. - view more
  • Andrew S., G., Paula I., S., Poppy Sephton, C., Aleksandra, B., Richard, H., Giurisato, E., et al. (2017). Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. SCIENCE ADVANCES, 3(8), Article number e1700898 [10.1126/sciadv.1700898]. - view more
All publications